Guillemette G, Guillon G, Marie J, Pantaloni C, Balestre M N, Escher E, Jard S
J Recept Res. 1984;4(1-6):267-81. doi: 10.3109/10799898409042554.
Angiotensin receptors from rat liver were labeled using four different ligands: (Sar1-(3H)Tyr4)-Angiotensin ll ((3H)SarAll); (Sar1-(3H)Tyr4-lle8)-Angiotensin ll ((3H)SarlleAll); (Sar1-(125I) Tyr4-(4'-N3) Phe8)-Angiotensin ll (IN3All); (Sar1-(125I)Tyr4-(4'N3D-Phe)8)-Angiotensin ll (IN3DPheAll). (3H)SarAll and IN3All behaved like agonists and (3H)SarlleAll and IN3DPheAll like antagonists. All four ligands labeled the same population of sites. The azido derivatives allowed covalent labeling of receptors with a high yield (about 40%). Membranes were solubilized by Triton X-100 under experimental conditions which ensured complete solubilization of the liganded receptors in a stable form (less than 40% dissociation after 20 h). The apparent size of liganded angiotensin receptors was determined by gel filtration on Ultrogel ACA-34 columns and by SDS gel electrophoresis (in the case of covalent labeling). The apparent Stokes radius of solubilized angiotensin receptors was different wether the receptor was labeled with an agonist (Stokes radius = 6.2 +/- 0.1 nm (6) after labeling with (3H)SarAll) or with an antagonist (Stokes radii of 5.5 +/- 0.1 (7), and 5.6 +/- 0.1 nm (4) after labeling with (3H)SarlleAll and IN3DPheAll respectively). After covalent labeling with IN3All angiotensin receptors were eluted as a mixture of light and heavy forms. SDS gel electrophoresis revealed only one molecular entity of Mr 64,000. It is concluded that binding of an agonist to liver angiotensin receptors triggers or stabilizes an interaction with another membrane component involved in the coupling of the receptor to its primary effector.
(Sar1-(3H)Tyr4)-血管紧张素II((3H)SarAll);(Sar1-(3H)Tyr4-Ile8)-血管紧张素II((3H)SarlleAll);(Sar1-(125I)Tyr4-(4'-N3)Phe8)-血管紧张素II(IN3All);(Sar1-(125I)Tyr4-(4'N3D-Phe)8)-血管紧张素II(IN3DPheAll)。(3H)SarAll和IN3All表现为激动剂,(3H)SarlleAll和IN3DPheAll表现为拮抗剂。所有四种配体标记的是同一群位点。叠氮衍生物能够以高产率(约40%)对受体进行共价标记。在确保配体结合的受体以稳定形式完全溶解(20小时后解离小于40%)的实验条件下,用Triton X-100溶解膜。通过在Ultrogel ACA-34柱上进行凝胶过滤以及SDS凝胶电泳(在共价标记的情况下)来测定配体结合的血管紧张素受体的表观大小。溶解的血管紧张素受体的表观斯托克斯半径有所不同,这取决于受体是用激动剂标记(用(3H)SarAll标记后斯托克斯半径 = 6.2 ± 0.1 nm (6))还是用拮抗剂标记(分别用(3H)SarlleAll和IN3DPheAll标记后斯托克斯半径为5.5 ± 0.1 (7)和5.6 ± 0.1 nm (4))。用IN3All进行共价标记后,血管紧张素受体以轻、重两种形式的混合物被洗脱。SDS凝胶电泳仅显示出一个分子量为64,000的分子实体。结论是激动剂与肝脏血管紧张素受体的结合引发或稳定了与另一种参与受体与其主要效应器偶联的膜成分的相互作用。